What is the equity of Imugene this year?
Imugene has equity of 118.25 M AUD this year.
Imugene Equity 2024
Imugene Equity
118.25 M AUD
Ticker
IMU.AX
ISIN
AU000000IMU9
WKN
891460
In 2024, Imugene's equity was 118.25 M AUD, a -14.74% increase from the 138.7 M AUD equity in the previous year.
Imugene Aktienanalyse
What does Imugene do?
Imugene Ltd is an Australian biotechnology company focused on the development of immunotherapies for various diseases, including cancer and infectious diseases. The company was founded in 2014 and is headquartered in Sydney. Imugene's business model is based on collaboration with academic institutions and other biotechnology companies to identify and develop promising drug candidates. The company also works closely with clinical researchers and physicians to accelerate drug development and ensure they meet patient needs. Imugene specializes in four different areas: oncology, immunology, infectious diseases, and neuroscience. Each area focuses on the development of drugs for specific diseases and medical needs. In the field of oncology, Imugene is focused on developing immunotherapy products for the treatment of breast cancer, colon cancer, lung cancer, and other types of cancer. Immunotherapy aims to strengthen the body's immune system to better destroy cancer cells. In the field of immunology, Imugene is focused on developing immunotherapy products for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immunotherapy aims to modulate the immune system to eliminate disease-causing cells. In the field of infectious diseases, Imugene is focused on developing vaccines and products for the treatment of diseases such as COVID-19, influenza, hepatitis B, and HPV. Vaccines aim to activate the immune system to recognize and destroy pathogens before they can cause harm in the body. In the field of neuroscience, Imugene is focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. These drugs aim to stimulate the brain's neuroprotective mechanisms to reduce nerve damage. Imugene has several promising products in the pipeline that aim to demonstrate the efficacy and safety of immunotherapy and other therapies. The company has already conducted clinical trials for some of these products, while others are still in preclinical development. One of Imugene's key products is HER-Vaxx, a vaccine for the treatment of breast cancer that activates the body's immune system against the HER2 protein, which promotes cancer growth in some individuals. The vaccine has been tested in clinical trials and has shown promising results. Another promising product from Imugene is PD1-Vaxx, a vaccine for the treatment of lung cancer that targets the activation of an important immune cell sensor. Preliminary study results suggest that treatment with PD1-Vaxx is synergistic with checkpoint inhibitors, another type of cancer treatment medication. Imugene is also working on a range of products for the treatment of COVID-19, including IMM-013, a vaccine against SARS-CoV-2, and IMM-036, an antibody against the virus. These products are being tested in preclinical development and are aimed at helping to contain the spread of the pandemic. Overall, Imugene aims to develop innovative drugs for the treatment of various medical needs. The company relies on close collaboration with academic and clinical partners to accelerate drug development and ensure its products meet the highest standards of efficacy and safety. Imugene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Imugene's Equity
Imugene's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Imugene's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Imugene's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Imugene's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Imugene’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Imugene stock
What was the equity of Imugene compared to the previous year?
The equity of Imugene has increased/decreased by -14.74% decreased compared to the previous year.
What impact does a high equity have on investors of Imugene?
A high equity is advantageous for investors of Imugene as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Imugene?
A low equity can be a risk for investors of Imugene, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Imugene affect the company?
An increase in equity of Imugene can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Imugene affect the company?
A reduction in equity of Imugene can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Imugene?
Some factors that can affect the equity of Imugene include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Imugene so important for investors?
The equity of Imugene is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Imugene take to change the equity?
To change equity, Imugene can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Imugene pay?
Over the past 12 months, Imugene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Imugene is expected to pay a dividend of 0 AUD.
What is the dividend yield of Imugene?
The current dividend yield of Imugene is .
When does Imugene pay dividends?
Imugene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Imugene?
Imugene paid dividends every year for the past 0 years.
What is the dividend of Imugene?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Imugene located?
Imugene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Imugene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Imugene from 9/28/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.
When did Imugene pay the last dividend?
The last dividend was paid out on 9/28/2024.
What was the dividend of Imugene in the year 2023?
In the year 2023, Imugene distributed 0 AUD as dividends.
In which currency does Imugene pay out the dividend?
The dividends of Imugene are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Imugene
Our stock analysis for Imugene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
